DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
Steroid therapy is the first-line treatment for graft-versus-host disease (GVHD). If GVHD does not respond to initial therapies, doctors may consider chemotherapy, monoclonal antibodies ...
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...
The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback